Relmada Therapeutics, Inc. RLMD
Institutional shares held
12.3 Million
229K
calls
138K
puts
Total value of holdings
$33.9M
$628K
calls
$378K
puts
Market Cap
$78.7M
28,608,500
Shares Out.
Institutional ownership
43.12%
# of Institutions
81
We take great care to ensure that the data presented and summarized in this overview for RELMADA THERAPEUTICS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding RLMD
View all-
Franklin Resources Inc San Mateo, CA1.3MShares$3.58 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.26MShares$3.46 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA1.19MShares$3.26 Million0.01% of portfolio
-
Parsons Capital Management Inc1MShares$2.76 Million0.21% of portfolio
-
Palo Alto Investors LP Palo Alto, CA732KShares$2.01 Million0.33% of portfolio
-
Deep Track Capital, LP Greenwich, CT675KShares$1.86 Million0.08% of portfolio
-
Black Rock Inc. New York, NY573KShares$1.58 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny562KShares$1.55 Million0.0% of portfolio
-
Vestal Point Capital, LP New York, NY490KShares$1.35 Million0.12% of portfolio
-
Opaleye Management Inc. Boston, MA480KShares$1.32 Million0.28% of portfolio
Latest Institutional Activity in RLMD
Top Purchases
Top Sells
About RLMD
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
Insider Transactions at RLMD
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 22
2024
|
Charles J Casamento Director |
SELL
Bona fide gift
|
Direct |
13,000
-100.0%
|
-
|
|
Sep 11
2024
|
Maged Shenouda Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
24,120
+21.45%
|
$48,240
$2.95 P/Share
|
|
Sep 11
2024
|
Sergio Traversa Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
51,407
+11.81%
|
$102,814
$2.99 P/Share
|
|
Sep 10
2024
|
Maged Shenouda Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
21,118
+24.75%
|
$42,236
$2.73 P/Share
|
|
Sep 10
2024
|
Sergio Traversa Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
33,014
+9.03%
|
$66,028
$2.75 P/Share
|
|
Sep 09
2024
|
Paul Edward Kelly Director |
BUY
Open market or private purchase
|
Direct |
25,000
+10.54%
|
$50,000
$2.59 P/Share
|
|
Sep 09
2024
|
Maged Shenouda Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
8,194
+15.98%
|
$16,388
$2.55 P/Share
|
|
Sep 09
2024
|
Charles J Casamento Director |
BUY
Open market or private purchase
|
Direct |
13,000
+50.0%
|
$26,000
$2.56 P/Share
|
|
Sep 09
2024
|
Sergio Traversa Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
55,579
+15.65%
|
$111,158
$2.71 P/Share
|
|
Jan 31
2024
|
Chuck Ence CA and CO |
BUY
Open market or private purchase
|
Direct |
13,670
+25.97%
|
$54,680
$4.05 P/Share
|
|
Jan 31
2024
|
Maged Shenouda Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
6,875
+16.46%
|
$27,500
$4.06 P/Share
|
|
Jan 31
2024
|
Sergio Traversa Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
27,460
+10.11%
|
$109,840
$4.0 P/Share
|
|
Jan 30
2024
|
Chuck Ence CA and CO |
BUY
Open market or private purchase
|
Direct |
14,500
+36.43%
|
$43,500
$3.87 P/Share
|
|
Jan 30
2024
|
Maged Shenouda Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
15,000
+34.86%
|
$45,000
$3.89 P/Share
|
|
Jan 30
2024
|
Sergio Traversa Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
40,999
+15.92%
|
$122,997
$3.9 P/Share
|
|
Jan 29
2024
|
Chuck Ence CA and CO |
BUY
Open market or private purchase
|
Direct |
10,800
+50.0%
|
$32,400
$3.65 P/Share
|
|
Jan 29
2024
|
Maged Shenouda Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
10,800
+45.32%
|
$32,400
$3.65 P/Share
|
|
Jan 29
2024
|
Sergio Traversa Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
31,541
+15.23%
|
$94,623
$3.71 P/Share
|
|
May 23
2023
|
Cedric O'Gorman Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+49.7%
|
$30,000
$3.18 P/Share
|
|
Dec 08
2022
|
Sergio Traversa Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
55,250
+27.73%
|
$110,500
$2.1 P/Share
|
Last 12 Months Summary
Buy / Acquisition
403K
Shares
From
5
Insiders
| Open market or private purchase | 403K shares |
|---|
Sell / Disposition
13K
Shares
From
1
Insiders
| Bona fide gift | 13K shares |
|---|